{"filing":{"accession_number":"0001193125-26-345732","cik":"0001783328","ticker":"TCRX","company_name":"TScan Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tcrx-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-20260812.htm"},"events":[{"id":27026,"run_id":24595,"accession_number":"0001193125-26-345732","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"TScan Therapeutics issued a press release on August 12, 2026, announcing its financial results for the second quarter ended June 30, 2026, including revenue of $1.1 million, R\u0026D expenses of $23.4 million, net loss of $30.4 million, and cash position of $100.2 million. The disclosure is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and operational highlights. This is material to investors assessing the company's financial condition and runway.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28378,"accession_number":"0001193125-26-345732","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TScan Therapeutics issued a press release on August 12, 2026, announcing its financial results for the second quarter ended June 30, 2026, including revenue of $1.1 million, R\u0026D expenses of $23.4 million, net loss of $30.4 million, and cash position of $100.2 million. The disclosure is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and operational highlights. This is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:15:51.590503+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28378,"accession_number":"0001193125-26-345732","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TScan Therapeutics issued a press release on August 12, 2026, announcing its financial results for the second quarter ended June 30, 2026, including revenue of $1.1 million, R\u0026D expenses of $23.4 million, net loss of $30.4 million, and cash position of $100.2 million. The disclosure is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and operational highlights. This is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:15:51.590503+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-08-12"}]}